Carcinocythemia
Carcinocythemia is a rare and severe condition characterized by the presence of malignant carcinoma cells in the peripheral blood. This phenomenon is also known as carcinoma cell leukemia. It is a manifestation of advanced metastatic cancer and indicates a poor prognosis.
Pathophysiology[edit | edit source]
Carcinocythemia occurs when carcinoma cells from a primary tumor enter the bloodstream and circulate as free cells. These cells can originate from various types of carcinomas, including breast cancer, lung cancer, prostate cancer, and gastrointestinal cancer. The presence of these cells in the blood is indicative of widespread metastasis and significant tumor burden.
Clinical Presentation[edit | edit source]
Patients with carcinocythemia often present with symptoms related to their primary malignancy. Common symptoms include fatigue, weight loss, and anemia. Due to the high tumor burden, patients may also experience complications such as thrombocytopenia, leukopenia, and disseminated intravascular coagulation (DIC).
Diagnosis[edit | edit source]
The diagnosis of carcinocythemia is made through the identification of malignant cells in a peripheral blood smear. These cells are typically identified by their large size, irregular shape, and high nuclear-to-cytoplasmic ratio. Additional diagnostic tools may include flow cytometry, immunohistochemistry, and molecular diagnostics to confirm the origin and type of carcinoma cells.
Treatment[edit | edit source]
The treatment of carcinocythemia is challenging and primarily focuses on managing the underlying malignancy. Therapeutic options may include chemotherapy, targeted therapy, and immunotherapy. Supportive care measures are also essential to manage symptoms and complications such as anemia and DIC.
Prognosis[edit | edit source]
The prognosis for patients with carcinocythemia is generally poor due to the advanced stage of the disease and the extensive spread of cancer cells. The presence of carcinoma cells in the blood is associated with a high risk of mortality.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
